1. Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221. (December 2016) Authors: Tinker, A.; Hirte, H.; Provencher, D.; Butler, M.; Ritter, H.; Tu, D.; Paralejas, P.; Grenier, N.; Hahn, S.; Ramsahai, J.; Seymour, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗